Drug Trial Radar · NCT05276726
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Aug 17, 2022
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Allist Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
Conditions
- Non-small Cell Lung Cancer
Interventions
JAB 21822Drug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation phase Number of participants with dose limiting toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Dose Escalation phase: Number of participants with adverse eventsTime frame: Up to 3 years
- Dose Expansion phase: Objective response rate (ORR)Time frame: Up to 3 years - from baseline to confirmed Progressive Disease per RECIST.
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Research site08
Beijing, Beijing Municipality, China · Not yet recruiting
Research site09
Beijing, Beijing Municipality, China · Not yet recruiting
Research site021
Beijing, Beijing Municipality, China · Not yet recruiting
Research site02
Beijing, Beijing Municipality, China · Not yet recruiting
Research site01
Beijing, Beijing Municipality, China · Recruiting
Research site013
Beijing, Beijing Municipality, China · Not yet recruiting
Research site010
Chongqing, Chongqing Municipality, China · Not yet recruiting
Research site05
Xiamen, Fujian, China · Not yet recruiting
Research site011
Shenzhen, Guangdong, China · Not yet recruiting
Research site016
Nanning, Guangxi, China · Not yet recruiting
Research site017
Shijiazhuang, Hebei, China · Not yet recruiting
Research site018
Harbin, Heilongjiang, China · Not yet recruiting
Research site04
Zhengzhou, Henan, China · Not yet recruiting
Research site012
Changsha, Hunan, China · Not yet recruiting
Research site015
Changchun, Jilin, China · Not yet recruiting
Research site06
Shenyang, Liaoning, China · Not yet recruiting
Research site07
Shenyang, Liaoning, China · Not yet recruiting
Research site014
Hohhot, Neimenggu, China · Not yet recruiting
Research site020
Xi’an, Shanxi, China · Not yet recruiting
Research site03
Hubei, Wuhan, China · Not yet recruiting
Research site019
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.